News

Cancer Research4d
Trends in Cancer Incidence and Mortality Rates in Early-Onset and Older-Onset Age Groups in the United States, 2010–2019 - American Association for Cancer Research
We estimated age-standardized cancer incidence (2010–2019) and mortality rates (2010–2022) in the United States to investigate whether cancer rates have increased at younger ages. Fourteen cancers had ...
Cancer Research4d
Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity Available to Purchase - American Association for Cancer Research
We identified mutation-harboring precancerous cells that emerge via oligodendrocyte progenitor cell fate specification and contribute to the evolution of GBM with intratumoral molecular heterogeneity.
Cancer Research4d
Response and Resistance to RAS Inhibition in Cancer Available to Purchase - American Association for Cancer Research
AbstractRAS inhibition has the potential to transform cancer treatment for many patients. The landscape of RAS inhibitor therapies is rapidly evolving, with two mutant-selective KRAS inhibitors now ...
Cancer Research5d
Artificial Intelligence–Driven Cancer Diagnostics: Enhancing Radiology and Pathology through Reproducibility, Explainability, and Multimodality | Cancer Research | American ...
Abstract. The integration of artificial intelligence (AI) in cancer research has significantly advanced radiology, pathology, and multimodal approaches, offering unprecedented capabilities in image ...
Cancer Research5d
Paving a Path to Clinical Impact with Radiomics: Enabling Reproducibility and Reach Available to Purchase - American Association for Cancer Research
Abstract. Radiomics, the extraction of quantitative data from images, holds promise for noninvasively characterizing tumor phenotypes. Tools like LIFEx have improved the accessibility, transparency, ...
Cancer Research5d
Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors Available to Purchase - American Association for Cancer Research
Chimeric antigen receptor (CAR) T-cell therapy has improved outcomes for patients with chemotherapy-resistant B-cell malignancies. However, CAR T-cell treatment of patients with solid cancers has been ...
Cancer Research5d
Multitask Deep Learning Based on Longitudinal CT Images Facilitates Prediction of Lymph Node Metastasis and Survival in Chemotherapy-Treated Gastric Cancer | Cancer Research ...
Accurate preoperative assessment of lymph node metastasis (LNM) and overall survival (OS) status is essential for patients with locally advanced gastric cancer receiving neoadjuvant chemotherapy, ...
Cancer Research6d
Ribociclib in Sequential Combination with Doxorubicin in Anthracycline-Naïve Advanced Soft-Tissue Sarcomas: Results of a Dose-Finding Phase Ib Study - American Association for ...
Doxorubicin-naïve patients with metastatic soft-tissue sarcoma were enrolled in this phase Ib study. Every 21 days, subjects received ribociclib daily for 7 days followed by 3 days of no treatment ...
Cancer Research6d
Antitumor Immunity Mediated by Engineered Stem Cells Exploiting TRAIL-Induced Cell Death and FLT3L Immunomodulation Available to Purchase - American Association for Cancer Research
AbstractPurpose:. Death receptor (DR)–targeted therapies offer a promising tumor cell–specific therapeutic strategy for highly malignant brain tumors, such as glioblastoma (GBM). However, whether ...
Cancer Research6d
Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα Open Access - American Association for Cancer Research
There is a strong unmet need for salvage therapy for the large subset of patients with melanoma that progresses after immune checkpoint blockade. We evaluated the safety and efficacy of adoptively ...
Cancer Research6d
Antibody–Drug Conjugates in Non–Small Cell Lung Cancer: Where Are the Target and the Biomarker? Available to Purchase - American Association for Cancer Research
Summary. Antibody–drug conjugates are an emerging treatment of non–small cell lung cancer. Some do not require biomarkers, whereas others require mutations and/or protein expression. New diagnostic ...
Cancer Research6d
Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials - American Association for Cancer Research
Abstract. Conducting phase I trials is particularly challenging when dealing with late-onset dose-limiting toxicity (DLT) or when patient accrual is rapid relative to the DLT assessment window. In ...